Get the Stockscreener App
4.20
19.23%
-1.00
After Hours:
4.1711
-0.0289
-0.69%
Dermata Therapeutics Inc stock is currently priced at $4.20, with a 24-hour trading volume of 57,531.
It has seen a -19.23% decreased in the last 24 hours and a +1,324% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $5.08 pivot point. If it approaches the $3.55 support level, significant changes may occur.
Previous Close:
$5.20
Open:
$4.94
24h Volume:
57,531
Market Cap:
$1.87M
Revenue:
-
Net Income/Loss:
$-7.79M
P/E Ratio:
-0.5237
EPS:
-8.02
Net Cash Flow:
$-6.41M
1W Performance:
+1,071%
1M Performance:
+1,324%
6M Performance:
+500.00%
1Y Performance:
+56.13%
1D Range:
$4.20
$4.94
52W Range:
$0.232
$5.79
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Name
Dermata Therapeutics Inc
Sector
Industry
Phone
858 800 2543
Address
3525 Del Mar Heights Road, Suite 332, San Diego
Dermata Therapeutics Inc Stock (DRMA) Latest News
Dermata Therapeutics announces exercise of warrants for $2.66M - TipRanks.com - TipRanks
TipRanks
Dermata Therapeutics announces warrant exercise and new issuance - Investing.com
Investing.com
Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under ... - Yahoo Finance
Yahoo Finance
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results - Yahoo Finance
Yahoo Finance
Dermata Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview - XM
XM
Dermata Therapeutics Enhances Equity Plan and Approves Stock Split - TipRanks.com - TipRanks
TipRanks
Dermata Therapeutics Inc Stock (DRMA) Financials Data
Dermata Therapeutics Inc (DRMA) Net Income 2024
DRMA net income (TTM) was -$7.79 million for the quarter ending December 31, 2023, a +18.90% increase year-over-year.
Dermata Therapeutics Inc (DRMA) Cash Flow 2024
DRMA recorded a free cash flow (TTM) of -$6.41 million for the quarter ending December 31, 2023, a +27.45% increase year-over-year.
Dermata Therapeutics Inc (DRMA) Earnings per Share 2024
DRMA earnings per share (TTM) was -$4.043 for the quarter ending December 31, 2023, a +71.86% growth year-over-year.
About Dermata Therapeutics Inc
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions. The company was founded in 2014 and is headquartered in San Diego, California.
0.77%
1.20%
Cap:
|
Volume (24h):